COL6A3
COL6A3 (Collagen alpha-3(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Melanoma.
Overview
Collagen VI acts as a cell-binding protein.
IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Melanoma. In OnCo, 1 product record names it (Vimseltinib).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · COL6A3 (Collagen alpha-3(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Melanoma.
- 1 · What it is
COL6A3 (Collagen alpha-3(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Melanoma.
- 2 · What goes wrong in cancer
Collagen VI acts as a cell-binding protein. Location: Secreted, extracellular space, extracellular matrix (UniProt).
- 3 · How drugs use it
No product in this corpus aims at COL6A3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:2213 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P12111 (protein name, function text, keywords and locations (REST API)); IntOGen COL6A3 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Collagen VI acts as a cell-binding protein. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 2q37.3 (HGNC).
- Melanoma: IntOGen driver in 1 cohort (MEL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: 1 OnCo product record names it; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"COL6A3" OR ABSTRACT:"COL6A3" OR TITLE:"collagen type VI alpha 3 chain" OR ABSTRACT:"collagen type VI alpha 3 chain" OR TITLE:"Collagen alpha-3 VI chain" OR ABSTRACT:"Collagen alpha-3 VI chain") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about COL6A3, not a curated reading list.